Related Experiment Video

Updated: May 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

DYRK1A kinase inhibitors with emphasis on cancer

A Ionescu1, F Dufrasne, M Gelbcke

  • 1Laboratoire de Chimie Organique, Faculté des Sciences, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Mini Reviews in Medicinal Chemistry
|September 29, 2012
PubMed

Insights

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) drives cancer cell resistance to apoptosis and promotes aggressive tumor behavior. Inhibiting DYRK1A kinase activity offers a promising therapeutic strategy for various cancers and neurological diseases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Neuroscience

Background:

  • Cancer cells, including gliomas, melanomas, and lung cancers, often resist apoptosis and chemotherapy.
  • Multidrug resistance and resistance to pro-apoptotic stimuli are significant challenges in cancer treatment.
  • The DYRK1A kinase plays a crucial role in cancer cell proliferation, migration, and survival, contributing to aggressive disease phenotypes.

Purpose of the Study:

  • To review compounds that inhibit the DYRK1A kinase.
  • To analyze the implications of DYRK1A in cancer and neurological diseases.
  • To guide researchers in enhancing anti-DYRK1A compound activity.

Main Methods:

  • Literature review of compounds targeting DYRK1A.
  • Analysis of DYRK1A's role in cancer cell resistance and proliferation.
  • Examination of DYRK1A's involvement in neurological processes and neoangiogenesis.

Main Results:

  • DYRK1A kinase is implicated in resistance to apoptosis and multidrug resistance in various cancers.
  • DYRK1A activity promotes cancer cell proliferation, migration, and reduced cell death.
  • DYRK1A is also involved in neurological diseases and the formation of new blood vessels.

Conclusions:

  • DYRK1A kinase is a significant therapeutic target for cancer treatment.
  • Inhibiting DYRK1A may overcome chemoresistance and reduce tumor aggressiveness.
  • DYRK1A's dual role in cancer and neuroscience highlights its importance in both fields.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: